Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells
/in Dendritic Cells, International Publications, Malignant Pleural MesotheliomaThe large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC)
/in Dendritic Cells, International Publications, NSCLCPhenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination
/in Breast Cancer, Dendritic Cells, International Publications[Combined radiotherapy and endovascular x-ray therapy for invasive cancer of the urinary bladder]
/in Dendritic Cells, International Publications, Urothelial CarcinomaTherapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy
/in Cervical Cancer, Dendritic Cells, International PublicationsChemo-immunotherapy of breast cancer using vesiculated alpha-tocopheryl succinate in combination with dendritic cell vaccination
/in Breast Cancer, Dendritic Cells, International PublicationsImmunotherapy and cancer vaccines in the management of breast cancer
/in Breast Cancer, Dendritic Cells, International PublicationsDendritic cells in clinical trials for multiple myeloma
/in Dendritic Cells, International Publications, Multiple MyelomaVaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12
/in Dendritic Cells, Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer